5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma
Authors
Robert, CSchachter, J
Long, GV
Arance, A
Grob, JJ
Mortier, L
Daud, A
Carlino, MS
McNeil, C
Lotem, M
Larkin, J
Lorigan, Paul C
Neyns, B
Blank, CU
Hamid, O
Petrella, TM
Anderson, J
Krepler, C
Diede, SJ
Ribas, A
Affiliation
Gustave Roussy and Paris-Sud University, Villejuif,Issue Date
2019
Metadata
Show full item recordCitation
Robert C, Schachter J, Long G, Arance A, Grob J, Mortier L, et al. 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma. Cancer Res. 2019;79(13).Journal
Cancer ResearchDOI
10.1158/1538-7445.AM2019-CT188Additional Links
https://dx.doi.org/10.1158/1538-7445.AM2019-CT188Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.AM2019-CT188